Organoids Market Size Report | Analysis and Forecast 2030

Organoids Market Forecast to 2030 - Global Analysis By Type (Stomach, Intestine, Liver, Pancreas, Lung, Brain, Kidney, and Others), Application (Developmental Biology, Disease Pathology of Infectious Disease, Regenerative Medicine, Drug Toxicity & Efficacy Testing, Drug Discovery & Personalized Medicine, and Others), Source (Pluripotent Stem Cells and Organ-specific Adult Stem Cells), and Geography

Publication Month : Aug 2023

  • Report Code : TIPRE00017616
  • Category : Biotechnology
  • Status : Published
  • No. of Pages : 175
Inquire Before Buy



[Research Report] The organoids market is expected to grow from US$ 2,507.28 million in 2022 to US$ 12,206.15 million by 2030; it is estimated to record a CAGR 21.9% during 2022–2030.

Market Insights and Analyst View:

The increasing demand for tumor modeling and biobanking and growing adoption of personalized drugs are the among the factors driving the organoids market expansion. Additionally, rising focus on developing alternatives for animal testing models support are expected to boost the organoids market growth. Animal models are used widely in biomedical research for human-specific diseases. However, various drug toxicology studies demonstrate that animal models cannot always predict human drug response. Therefore, to develop alternative testing models that can provide an environment with full equivalence to the human body, various institutes are developing alternative methods for drug development and biomedical research. Also, the use of organoids has increased as an alternative to animal testing after placing restrictions on animal testing by different governments.

The organoids market key players are focusing on strategic initiatives by collaborations to expand their geographic reach and enhance capacities to cater to a large customer base. For instance, in August 2021, STEMCELL Technologies and Hubrecht Organoid Technology (HUB) have signed an agreement to use tissue-derived organoids—including lung, intestinal, and liver organoids—in preclinical toxicology screening and non-cancer drug development services to be offered by the Contract Assay Services division of STEMCELL. Factors such as increasing demand for tumor modeling and biobanking and growing adoption of personalized drugs, bolstering the organoids market growth. Additionally, rising focus on developing alternatives for animal testing models are driving the organoids market growth.

Growth Drivers and Challenges:

Organoids are microscopic and self-organizing 3D structures grown from stem cells in vitro. They review various structural and functional characteristics of their in vivo counterpart organs. This multipurpose technology has led to several novel human cancer models. It is now possible to create indefinitely expanding organoids starting from the tumor tissue of individuals suffering from a range of carcinomas. Alternatively, CRISPR-based gene modification allows the engineering of organoid models of cancer by introducing any combination of cancer gene alterations to normal organoids. Tumor organoids, when combined with immune cells and fibroblasts, become a model for the cancer microenvironment enabling immune-oncology applications. Also, recent studies have proved that organoids have a place in personalized medicine approaches.

The constant progress in organoid technology has paved the way for tumors and patient-centric 3D cultures of cells isolated from tumor biopsies. Over the past few decades, organoids have been generated from diverse human cancers associated with breast, colon, pancreas, prostate, bladder, and liver. Studies involving these models help in providing key facts about these malignancies. Due to constant advancements in the current scenario, tumoroid lines are increasingly being passed in vitro, opening new paths for a range of downstream applications. Moreover, 3D-based cultures offer added advantages over conventional 2D cancer-derived cell lines. Further, recent research and development activities have specified that tumoroid culturing is highly effective in allowing the collection of various cancer subtypes from a large pool of patients. As organoids can be easily derived and expanded from single cancer cells, the adoption of organoids to mimic intratumor diversification in culture is increasing, which, in turn, is propelling the global organoids market.

Companies have been developing innovative biobanks for storing several biological samples, including tumors. For instance, OrganoidBase (developed by Crown Bioscience) consists of 342 tumor organoid models derived from patient-derived xenograft (PDX) models [i.e., PDX-derived organoids (PDXOs)]. PDXOs offer detailed information on histopathology, IC50, genomic, and transcriptomic analysis data associated with drug response; it also has an additional 217 models from primary patient samples. These PDXO models have varied indications, with multiple models derived from over 20 organ and tissue types. Crown Biosciences commercializes organoids in a 3D in vitro model derived using IP-protected Hubrecht Organoid Technology (HUB) protocols. Thus, such innovations are driving the market growth.

Customize Research To Suit Your Requirement

We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.

Organoids Market: Strategic Insights

Market Size Value inUS$ 2,507.28 million in 2022
Market Size Value byUS$ 12,206.15 million by 2030
Growth rateCAGR 21.9% from 2022 to 2030
Forecast Period2022-2030
Base Year2022
Analyst Image


Have a question?

Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.

Analyst Image  Speak to Analyst

Organoids Market Segmentation and Scope:

The “Global Organoids Market” is segmented based on type, application, source, and geography. The organoids market, by type, is segmented into intestine, liver, stomach, pancreas, lung, brain, kidney, and others. Based on application, the organoids market is segmented into developmental biology disease, pathology of infectious disease, regenerative medicine, drug toxicity and efficacy testing, drug discovery and personalized medicine, and others. By source, the organoids market is bifurcated into pluripotent stem cells and organ-specific adult stem cell. Geographically, the organoids market is divided into North America (the US, Canada, and Mexico), Europe (Germany, France, Italy, the UK, Russia, and Rest of Europe), Asia Pacific (Australia, China, Japan, India, South Korea, and Rest of Asia Pacific), Middle East & Africa (South Africa, Saudi Arabia, UAE, and Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and Rest of South & Central America).

  • Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
  • Request discounts available for Start-Ups & Universities

Segmental Analysis:

Based on type, the organoids market is segmented into stomach, intestine, liver, pancreas, lung, brain, kidney, and others. The intestine segment accounted for the largest market share in 2022 and is expected to register a CAGR of 21.6% during the forecast period. The market position of this segment is due to the prevalence of inflammatory bowel diseases (IBDs). IBDs, such as Crohn's disease (CD) and ulcerative colitis (UC), are common worldwide. In the last decade, there has been a dramatic shift in the availability of tools and model systems that are used to study the intestinal epithelium. The development and adoption of intestinal organoid cultures have been the core of this movement. Simultaneously, various experimental techniques—including novel genetic manipulation tools, in vitro disease modeling approaches, innovative co-culture systems with autologous cell types or bacteria, and viral infection models—were developed to evaluate a scientifically synergistic effect with intestinal organoid cultures.  The aforementioned factors are responsible for driving the organoids market growth for the segment.

Based on application, the organoids market is segmented into developmental biology disease, pathology of infectious disease, regenerative medicine, drug toxicity & efficacy testing, drug discovery & personalized medicine, and others. The developmental biology disease segment held the largest share of the market in 2020 and is likely to grow at the highest rate during the forecast period. Human organoid cultures can be used to study human development and model diseases with the same depth of analysis that is customary for research with nonhuman model organisms. Technological advancements in 3D bioprinting have shown a massive potential to facilitate organ development, as the time required for organoid culturing is much less than traditional tissue culture methods. Patient-derived human organoid studies may create new opportunities in the fields of tissue engineering and regenerative medicine, generating knowledge and tools for preclinical testing in drug development studies. The growth of the organoids market for developmental biology applications is attributed to the acceptance received by organoids as the primary investigative research tool in human developmental biology. Moreover, organoids derived from embryonic stem cells offer a complete understanding of embryonic process development and insights into stem cell development.

Based on source, the organoids market is bifurcated into pluripotent stem cells and organ-specific adult stem cell. The pluripotent stem cells segment held a larger share of the market in 2020 and is likely to grow at a higher rate during the forecast period. Induced pluripotent stem cells (iPSCs) are perceived as an essential resource for regenerative medicine to replace diseased or damaged tissues. iPSCs have numerous biomedical applications in fundamental research, drug screening, toxicological studies, disease modeling, and cell therapy. These cells can be potentially used in cell replacement therapy to treat patients with cellular diseases. Thus, they are widely used for developing an organoid in vitro. In addition, pluripotent cells are used in biobanking to preserve patient-derived stem cells in various applications, which can be used in research and therapeutics. In November 2017, Cincinnati Children's scientists launched the Center for Stem Cell and Organoid Medicine (CuSTOM), which uses pluripotent stem cells to mimic organoids.      

Organoids Market, by Source– 2020 and 2028

  • Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
  • Request discounts available for Start-Ups & Universities

Regional Analysis:

Based on geography, the organoids market is divided into five key regions: North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa. In 2020, North America held the largest share of the global organoids market, and Asia Pacific is estimated to register the highest CAGR during the forecast period. North America is the largest market for organoids in biobanking, with the US holding the largest market share, followed by Canada. The US market is primarily driven by increasing research and development activities, rising demand for tissue engineering and organ transplantation, and high adoption rate of organoids. Thus, owing to the wide range of benefits, there is a significant demand for organoids in the US. Research funding and venture capital investments have significantly increased the development of human organoids. In November 2020, Megan McCain of the USC Viterbi Department of Biomedical Engineering collaborated with Giorgia Quadrato and Leonardo Morsut of the USC Keck School of Medicine's Department of Stem Cell Biology and Regenerative Medicine on a four-year, US$ 1.5 million National Science Foundation-funded project. With this project, the firm looks forward to improving the process of developing brain organoids and making end products more consistent and reliable for brain researchers. Similarly, in 2019, the US National Institutes of Health allocated a total funding budget of US$ 39.1 billion, of which US$ 6.25 billion (16%) was invested into cancer research and US$ 701 million to breast cancer research. Additionally, UC San Diego researchers are developing human organoids—miniaturized, 3D versions of an organ produced from reprogrammed stem cells in the lab. These models, sometimes called “mini-brains” or “organs-in-a-dish,” have empowered scientists to study biological functions, diseases, and treatments more realistically and in greater detail. Hence, apart from the demand for organoids, the growing research activities to reduce cancer prevalence is also driving the organoids market growth in North America.   

Industry Developments and Future Opportunities: 

Various initiatives taken by key players operating in the global organoids market are listed below:

  1. In April 2023, InSphero AG announced that the company is making their patented Akura 96 and 384 Spheroid Microplates available to researchers in the Indian market by signing a distribution agreement with Bionova Supplies in biotechnology and scientific instruments.
  2. In March 2023, Molecular Devices, LLC. collaborated with HUB Organoids (HUB) for continued development of next-generation 3D biology technologies that drive step-change reduction in pre-clinical to clinical drug attrition. Under the terms of the agreement, Molecular Devices will license cutting-edge HUB Organoid Technology to work with patient-derived intestinal organoids, expanding Molecular Devices’ 3D biology expertise beyond organoid types such as the heart and brain.
  3. In February 2023, Thermo Fisher Scientific and Celltrio collaborated to bring a fully automated cell culture system to biotherapeutics customers. The collaboration will integrate the Thermo Scientific Momentum workflow scheduling software with the Celltrio RoboCell cell line automation platform to address the unmet market need for high-throughput automated cell line culturing and maintenance.    

COVID-19 Impact:

Stem-cell-derived organoid models have received high focus on a new treatment and research method for COVID-19. Additionally, clinical studies reveal that various organoids derived from stem cells offer an ideal and sufficient model to explore the possibility and mechanism of SARS-CoV-2 infecting multiple organs that can better serve clinical treatment research. Moreover, stem cell therapy amid the pandemic is not only available for severe COVID-19 patients but also for those who recovered from severe COVID-19 complications to repair damaged lungs making it an ideal treatment option.

Several research groups have successfully shown that SARS-CoV-2 can infect and propagate in primary human organoids derived from the liver and gut and in pluripotent stem cell-derived organoids modeling blood vessels in the kidney. Moreover, it has been shown that the viral infection of the human blood vessel and kidney organoids can be inhibited by human recombinant soluble ACE2, a drug candidate initially developed for SARS-CoV-2. Structural studies of the spike proteins of SARS-CoV-2 and SARS-CoV bound to ACE2 predicted a similar result. These studies have provided additional evidence that human organoids can serve as a useful research platform for studying human diseases, including the outbreak of new viruses such as SARS-CoV-2. Further, strategic activities by the researcher, along with funding, will have a positive impact on the market. For instance, the Government of Canada is investing US$ 27 million in coronavirus research. The investment will support 47 projects across two research areas to ensure a balanced research response. Human and animal organoids are now proving their value as an experimental virology platform. Usage of the organoid models to reveal how the COVID-19 virus affects several intestinal cells is expected to drive organoids in research. Scientists have been using these systems for the testing and identification of promising medications. Thus, the collaboration is expected to impact the organoids market in the coming few years positively.

Competitive Landscape and Key Companies:

Some of the prominent players operating in the global organoids market are STEMCELL Technologies Inc., Cellesce Ltd, Hubrecht Organoid Technology, Definigen, Organoid Therapeutics, 3Dnamics Inc., Thermo Fisher Scientific Inc, Corning Inc, Merck KGaA, and InSphero. These companies focus on new product launches and geographical expansions to meet the growing consumer demand worldwide and increase their product range in specialty portfolios. They have a widespread global presence, which provides them to serve a large set of customers and subsequently increases their market share.

Report Coverage
Report Coverage

Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
Segment Covered

Type, Application, Source, and Geography

Regional Scope
Regional Scope

North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
Country Scope

Argentina, Australia, Brazil, Canada, China, France, Germany, India, Italy, Japan, Mexico, Saudi Arabia, South Africa, South Korea, Spain, United Arab Emirates, United Kingdom, United States

Frequently Asked Questions

What is the market CAGR value of organoids market during forecast period?

The CAGR value of the organoids market during the forecasted period of 2022-2030 is 21.9%.

What are the driving factors for the organoids market across the globe?

Key factors such as the increasing demand for tumor modeling and biobanking, growing adoption of personalized drugs, and rising focus on developing alternatives for animal testing models are expected to boost the market growth for the organoids over the years.

What are organoids?

An organoid is a miniaturized and simplified version of an organ fabricated in vitro in three dimensions that mimics the essential functional, structural, and biological complexity of that organ. These tissue biorepositories provide a record of genetic heterogeneity between patients and present patient-derived samples that can be propagated for research purposes, making them invaluable tools for basic research. Organoid systems are currently used to model cancer development and treatment. Cancer research has been limited due to the lack of in vitro models that can accurately replicate the physiology of the original tumor. There are potentially as many types of organoids as different tissues and organs in the body. Researchers have created organoids that resemble the brain, kidney, lung, intestine, stomach, and liver. However, organoids lack a vasculature and are cultured using static methods. As the organoids grow, the cells in the center need more nutrients, and waste exchange becomes difficult.

Which type led the organoids market?

The intestine segment held the largest share of the market in the global organoids market and held the largest market share of 23.2% in 2022.

Which application held the largest share in the organoids market?

The developmental biology segment dominated the global organoids market and accounted for the largest market share of 29.4% in 2022.

Which source held the largest share in the organoids market?

The pluripotent stem cells segment dominated the global organoids market and held the largest market share of 72.5% in 2022.

Which are the top companies that hold the market share in organoids market?

Thermo Fisher Scientific Inc. and Merck KgaA are the top two companies that hold huge market shares in the organoids market.

Which region is expected to witness significant demand for organoids market in the coming years?

Global organoids market is segmented by region into North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America. In North America, the U.S. is the largest market for organoids. The region is expected to witness a consistent growth owing to factors such as rising number of patients suffering from chronic conditions and viral diseases, increasing activities in research and development, commercialization of organoid models, and breakthroughs in stem cell research are the key factors propelling the market for organoids. Also, the growing funding and grants for organoid development are favoring market expansion. The Asia Pacific region is expected to account for the fastest growth in the organoids market. The market in the region is likely to continue to grow at the fastest rate during the forecast period owing to factors such as increasing incidences of cancer, growing demand for gene mutation and cancer research, government efforts to raise awareness related to human organoids, supportive regulations for the development and commercialization of advanced human organoids products, and increased funding for organoids research.

Who are the key players in the organoids market?

The organoids market majorly consists of the players such STEMCELL Technologies Inc. Cellesce Ltd, Hubrecht Organoid TechnologY, Definigen, Organoid Therapeutics, 3Dnamics Inc., Thermo Fisher Scientific Inc, Corning Inc, Merck KgaA, InSphero among others.

The List of Companies - Organoids Market

  1. STEMCELL Technologies Inc
  2. Cellesce Ltd
  3. Hubrecht Organoid Technology
  4. Definigen
  5. Organoid Therapeutics
  6. PeproTech, Inc
  7. Thermo Fisher Scientific Inc
  8. Corning Inc
  9. Merck KGaA
  10. InSphero.

The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

  1. Data Collection and Secondary Research:

As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.

  1. Primary Research:

The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

A typical research interview fulfils the following functions:

  • Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
  • Validates and strengthens in-house secondary research findings
  • Develops the analysis team’s expertise and market understanding

Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

  • Industry participants: VPs, business development managers, market intelligence managers and national sales managers
  • Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

Below is the breakup of our primary respondents by company, designation, and region:

Research Methodology

Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

  1. Data Analysis:

Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

  • 3.1 Macro-Economic Factor Analysis:

We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

  • 3.2 Country Level Data:

Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

  • 3.3 Company Profile:

The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

  • 3.4 Developing Base Number:

Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

  1. Data Triangulation and Final Review:

The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.

Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Related Reports